Beijing Haizhi Technology Group has received CSRC filing approval for its proposed Hong Kong IPO of up to 47,584,600 shares and conversion of 372,400,480 domestic shares held by 40 shareholders into H-shares for circulation. The filing is valid for 12 months, requires reporting of material events and post-listing details within 15 working days, and does not represent CSRC's endorsement of investment value or accuracy of materials.
Hongxing ColdChain (Hunan) Co., Ltd. launched its public offering on December 31, 2025, with an issue price of HK$12.26 per share, a board lot of 500 shares, and an entry cost of approximately HK$6,191.83. The company plans to raise approximately HK$252 million and is expected to list on January 13, 2026. As a leading enterprise in the cold chain market in Central China and Hunan Province, the company demonstrates strong regional competitive advantages and profitability through its integrated "warehousing + retail stores" business model. However, it also faces risk challenges such as high regional concentration of its business, continuous decline in operations at its northern base, intensified market competition, and short-term profit pressure brought about by expansion.
TwinSolution Technology recently filed for listing on the STAR Market, with Huatai United Securities as the sponsor. According to Yole data and the company's prospectus, its chip testing interface revenue ranked first in mainland China in 2024, with customers including NVIDIA, Apple and other well-known enterprises. Financial data shows the company's 2024 revenue was RMB 331 million, with a three-year compound annual growth rate of 41.54%, though net profit experienced fluctuations. The IPO proceeds are intended primarily for construction of testing interface and probe card production bases, R&D center projects, and working capital supplementation.
EACON Group recently filed another listing application with the Hong Kong Stock Exchange, with Guotai Haitong Securities as the sole sponsor. According to Frost & Sullivan, the company is China's largest provider of autonomous driving solutions for mining areas by number of active mining trucks and 2024 revenue. The prospectus shows 2024 revenue of RMB 986 million and a three-year compound annual growth rate of 305.8%, though net losses continued to widen during the reporting period.
EVE Energy Co., Ltd. (300014.SZ) formally submitted an application for a main board listing on the Hong Kong Stock Exchange on January 2, with CITIC Securities acting as the sole sponsor. The company is one of the few globally integrated lithium battery platform enterprises covering consumer, power, and energy storage batteries across all application scenarios. In 2024, it ranked second globally in energy storage battery shipments, while also maintaining leading positions in the consumer and power battery sectors.
OneRobotics (stock code: 06600.HK) was listed on the Hong Kong Exchanges and Clearing Limited (HKEX) on December 30. On the following day, its shares closed 9.21% higher at HK$80.65, with a market capitalization of nearly HK$18 billion, earning it the title of "the first AI Embodied Home Robot Stock". Founded in Shenzhen in 2015, the company is headquartered in the city and houses its global sales and intelligent computing hubs in Hong Kong, focusing on the R&D of AI home robots. It has secured strategic investment from the Hong Kong Investment Corporation Limited (HKIC) as well as early backing from renowned semiconductor experts Li Zexiang and Gao Bingqiang.
On December 30, 2025, Knowledge Atlas (02513.HK) officially launched its public offering, which will close on January 5, 2026, with an expected listing date of January 8, 2026. The offer price has been set at HK$116.20 per share, with a board lot of 100 shares, an entry cost of approximately HK$11,737.19, and a total fundraising amount of about HK$4.17 billion. Newtimespace observes that as one of the few domestic companies with full-stack, self-developed capabilities in large models, Knowledge Atlas is at the forefront in terms of technical prowess, open-source ecosystem, and commercialization efforts. However, it faces risks such as intense market competition and inclusion on the U.S. "Entity List," making its post-listing growth trajectory a key focus for market attention.
On December 30, 2025, Insilico Medicine, hailed as "the first AI-driven pharmaceutical stock on the Hong Kong stock market" and a strategic investment of the Hong Kong Investment Corporation Limited (HKIC), was listed on the Main Board of the Hong Kong Exchanges and Clearing Limited (HKEX). With a total fundraising of HK$2.277 billion, it has claimed the title of the largest IPO in the biopharmaceutical sector of the Hong Kong stock market in 2025, and its share price delivered an impressive performance on the debut day. It is reported that Biren Technology, another portfolio company of HKIC, is also set to list on the HKEX on January 2, 2026, which indicates that the effectiveness of HKIC’s diversified strategic investment layout continues to unfold.
